Bharat Biotech Seek Permit For Nasal COVID Vaccine's Phase 1 Trial

COVID-19 vaccine developer Bharat Biotech has applied to the Drug Controller General of India for Phase 1 trial of its intranasal COVID-19 vaccine. Touted as a potential game-changer, the vaccine is a pain-free needle-less method and does not require trained healthcare workers. Citing the efficacy on tests results done on rodents, Bharat Biotech said it could stimulate an immune response in the nose by protecting the point of entry of the virus.